戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ociceptin, while it did block the effects of endomorphin-2.
2  maximally effective concentration), but not endomorphin-2 (0.6 mM; an endogenous ligand for micro -o
3 austively stereodiversified library based on endomorphin-2 (1) to discover mu opioid receptor (MOR) l
4 slices with a micro-opioid receptor agonist (endomorphin-2, 100 nM).
5 -Me-Phe(4),Gly(5)-ol]-enkephalin (DAMGO) and endomorphin-2 activated inwardly rectifying K(+) current
6 or l-Pro, a more metabolically-stable d-Pro2-endomorphin-2 analog should produce longer analgesic act
7 lates, including enalaprilat, perindoprilat, endomorphin-2 and isoniazid, and subjected to biological
8 e exists for functional interactions between endomorphin-2 and MOR1.
9 ercising muscle and evoke a pressor reflex), endomorphin-2 and naloxone resulted in a significantly g
10 , N-MePhe(4), Gly-ol(5)]-enkephalin (DAMGO), endomorphin-2, and morphine in rat and mouse locus coeru
11                  A small proportion of these endomorphin-2 axons contained MOR1, but many of the dend
12 ts by [N-Phe(1)]-nociceptin-(1-13)-NH(2) and endomorphin-2 by naloxone, was not due to some nonspecif
13 ail-flick test, analgesia elicited by either endomorphin-2, d-Pro2-endomorphin-2 or Ala-Pyrrolidonyl-
14                                          The endomorphin-2 derivative displayed increased activity at
15  previously reported that microinjections of endomorphin-2 (E-2; an endogenous mu-receptor agonist) i
16                                       d-Pro2-endomorphin-2 (ED50=0.05 microg) was more potent than en
17 in-2 (ED50=0.05 microg) was more potent than endomorphin-2 (ED50=30 microg) in significantly increasi
18  functional domains of the endogenous opioid endomorphin-2 (EM-2) and the tachykinin SP, respectively
19 c.v.) injections of endomorphin-1 (EM-1) and endomorphin-2 (EM-2) in the rat brain to determine the s
20 us opioid peptides, endomorphin-1 (EM-1) and endomorphin-2 (EM-2), on mu opioid receptor (MOR) intern
21 activity of a constrained cyclic analogue of endomorphin-2 (EM-2: Tyr-Pro-Phe-Phe-NH(2)) and related
22                                              Endomorphin-2 (EM-2: Tyr-Pro-Phe-Phe-NH(2)) is an endoge
23         We find that the magnitude of spinal endomorphin 2 (EM2) antinociception not only varies with
24                                 We show that endomorphin-2 (EM2), an arrestin-biased ligand for micro
25 re and after systemic administration of EM1, endomorphin-2 (EM2), DAMGO, and morphine in the consciou
26 ously showed that intrathecal application of endomorphin 2 [EM2; the highly specific endogenous mu-op
27 el of pharmacological agonism confirmed that endomorphin-2 had a much lower operational efficacy for
28 idase IV plays a role in the inactivation of endomorphin-2 in vivo, and thereby modulates its central
29                                     However, endomorphin-2 induced faster desensitization of the K(+)
30 , has been described which should potentiate endomorphin-2-induced analgesia.
31  anatomical data support the hypothesis that endomorphin-2 is a ligand for MORs in the trigeminal dor
32        Together, these results indicate that endomorphin-2 is an arrestin-biased agonist at MOPr and
33                                              Endomorphin-2 is present in high density in the spinal a
34 sia elicited by either endomorphin-2, d-Pro2-endomorphin-2 or Ala-Pyrrolidonyl-2-nitrile returned aft
35 ia, and potentiated the analgesic actions of endomorphin-2, particularly on the tail-flick test.
36 d MOR1, but many of the dendritic targets of endomorphin-2 terminals contained MOR1.
37 , because the potencies of endomorphin-1 and endomorphin-2 to elicit internalization were unaffected
38 ason for this is likely to be the ability of endomorphin-2 to induce greater phosphorylation of MOPr
39 cells stably expressing MOPr, the ability of endomorphin-2 to induce phosphorylation of Ser375 in the
40             We confirmed the localization of endomorphin-2 to unmyelinated axons and axon terminals i
41 endomorphin 1 (Tyr-Pro-Trp-Phe-NH2; EM1) and endomorphin 2 (Tyr-Pro-Phe-Phe-NH2; EM2) in the rat cent
42 domorphin-1 (Tyr-Pro-Trp-Phe-NH(2); EM1) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH(2); EM2) have been loc
43 immunoreactive for the endogenous MOR ligand endomorphin-2 (Tyr-Pro-Phe-Phe-NH2) (EM-2) have been rep
44                            A second peptide, endomorphin-2 (Tyr-Pro-Phe-Phe-NH2), which differs by on
45                            The tetrapeptide, endomorphin-2 (Tyr-Pro-Phe-PheNH2) possesses high affini
46 estigated this phenomenon in more detail for endomorphin-2, using endogenous MOPr in rat brain as wel
47            Consistent with previous studies, endomorphin-2 was contained primarily in dense core vesi
48                 The present study found that endomorphin-2 was degraded approximately twice as fast t
49 , by dipeptidyl peptidase IV, whereas d-Pro2-endomorphin-2 was totally resistant to this enzyme's act
50                               The effects of endomorphin 2 were qualitatively similar.
51                                           If endomorphin-2 were an endogenous ligand for the MOR1, we
52 f bilorphin and the strongly arrestin-biased endomorphin-2 with the MOPr indicate distinct receptor i